Bionomics’ PTSD Candidate Clears Phase IIb Study, Stock Jumps 415%

Topline data from the Phase IIb ATTUNE trial showed that Bionomics’ investigational ion channel modulator BNC210 met the study’s primary endpoint, significantly reducing symptoms in patients with post-traumatic stress disorder, the company announced Thursday.